Tackling antimicrobial resistance in neonatal sepsis

7 Nov 2017

by Folgori L, Ellis SJ, Bielicki JA, Heath PT, Sharland M, Balasegaram M. The Lancet Global Health, November 2017, doi: 10.1016/S2214-109X(17)30362-5.

Summary: There are an estimated 2.9 million neonatal deaths every year, of which 23% are caused by infections. Antimicrobial resistance is a major challenge, since nearly half of the pathogens that cause severe neonatal bacterial infections are reported to be resistant to the first- and second-line WHO-recommended treatments. The article summarizes the current situation and describes the launch of GARDP’s neonatal sepsis programme. The specific aim of the NeoAMR Project is to develop two treatments: one for use in areas of high prevalence of ESBL Gram-negative bacteria, and one for use in situations with carbapenem-resistant Gram-negative bacteria. The NeoAMR Project will provide the general framework for the design and implementation of large-scale neonatal sepsis trials across different geographical settings.

We use cookies to provide you a better experience and understand how our site is being used. To consent to the use of cookies, click ‘Accept’. Learn more about our cookie and privacy policy.